Merck and Moderna announced in August that their personalized mRNA cancer vaccine demonstrated significant effectiveness in delaying both cancer recurrence and metastatic disease development in melanoma patients during a large Phase 3 trial. The companies are now preparing to seek regulatory approval for the treatment, marking a notable development for the cancer vaccine field. Patient Gary Keblish, who participated in the trial after undergoing surgery for melanoma, continues to work as a public school teacher and spoke about his experience at the STAT Summit.
The vaccine, chemically known as intismeran autogene, functions by analyzing individual tumors and using an algorithm to identify up to 34 mutant proteins that can be presented to the immune system. The treatment is administered in combination with Merck’s established immunotherapy Keytruda, which has been tested extensively over 15 years in thousands of clinical trials. The companies have focused their initial development on adjuvant settings—where the vaccine is given after surgical tumor removal—particularly in melanoma patients.
Merck R&D chief Dean Li and Moderna President Stephen Hoge outlined their strategy for future exploration at the summit, noting that they have deliberately chosen to focus on tumor types and settings where Keytruda has demonstrated efficacy, rather than pursuing cold tumors or advanced metastatic disease. Trials are currently underway in adjuvant settings for lung, kidney, and bladder cancers, while small studies in adjuvant pancreatic and gastric cancer are also in progress. The companies are also considering applications in early-stage tumors and in patients whose metastatic tumors have been shrunk by other treatments.
The executives emphasized that while the vaccine technology has limitations, the extensive data gathered from several thousand patients in their Phase 3 program provides an opportunity to refine the algorithm and improve the treatment further. Both Hoge and Li indicated they remain flexible about pivoting their strategy should positive data emerge in other settings, while defending their current approach as informed by their deep understanding of where immunotherapy mechanisms are most effective.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI